Pharmacogenomics: Bridging the gap between science and practice
Authors:
- Kelly C. LeeKLKelly C. Lee
- Joseph D. MaJMJoseph D. Ma
- Grace M. KuoGKGrace M. Kuo
- 1 January 2010
- journal article
- review article
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 50 (1) , e1-e17
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug BindingScience, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIVAIDS, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesJournal of Thrombosis and Thrombolysis, 2007
- Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug ResponseClinical Pharmacology & Therapeutics, 2007
- Economic and Developmental Considerations for Pharmacogenomic TechnologyPharmacoEconomics, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001